Antidepressants versus placebo for panic disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Guaiana, Giuseppe ^a   Barbui, Corrado ^b   Chiodo, Debbie ^c   Cipriani, Andrea ^b   Davies, Simon J C ^d   Koesters, Markus ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ADULT; ADVERSE OUTCOME; AGORAPHOBIA; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; HUMAN; PANIC; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 85041499654     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010676     Document Type: Article

References (39)

1. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290:921-8.
2. Altman DG, Bland MJ. Detecting skewness for summary information. BMJ 1996;313:1200.
3. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 2000;58:19-36.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Publishing, 1994.
5. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder. American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder. American Psychiatric Publishing, 2009.
6. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatrica Scandinavica 2002;106:163-7.
7. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19:567-96.
8. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al.Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170:477-80.
9. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology 1998;33:587-95.
10. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. Comparison of the indices and their use. Therapie 1999;54:405-11.
11. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clinical Neuropharmacology 1993;16:387-400.
12. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, et al.Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry 2003;160:1432-8.
13. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38:579-85.
14. Clark DB, Taylor CB, Roth WT, Hayward C, Ehlers A, Margraf J, et al.Surreptitious drug use by patients in a panic disorder study. American Journal of Psychiatry 1990;147:507-9.
15. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
16. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa. 2000 Oct 25-28th.
17. Eaton WW, Kessler RC, Wittchen H-U, Magee WJ. Panic and panic disorder in the United States. American Journal of Psychiatry 1994;151:413-20.
18. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
19. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-6.
20. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20:49-52.
21. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59:7-10.
22. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: ]
23. Goisman RM, Warshaw MG, Steketee GS, Fierman EJ, Rogers MP, Goldenberg I, et al.DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry 1995;152:1438-43.
24. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 2000;157:493-505.
25. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al.The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006;67:363-74.
26. Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue [in progress].
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
28. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63:415-24.
29. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al.Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry 2008;192:362-7.
30. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
31. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
32. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine 2009;6(6):e1000097.
33. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, et al.Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry 2008;1993:229-34.
34. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults [CG113]. London: National Institute for Health and Care Excellence, 2011.
35. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 2000;158:1989-92.
36. Sánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, Gómez-Conesa A. Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clinical Psychology Review 2010;30:37-50.
37. Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. Oxford University Press, 2009.
38. Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW. Pharmacologic treatment of panic disorder. Current Topics in Behavioral Neurosciences 2010;2:469-85.
39. Wade AG. Antidepressants in panic disorder. International Clinical Psychopharmacology 1999;14(Suppl 2):13-17.